CSPC Pharmaceutical Group (HKG:1093) said the new drug application for Anbenitamab in combination with its Docetaxel for Injection (Albumin-bound) was accepted by China's National Medical Products Administration.
The drug, co-developed by unit Shanghai JMT-BIO Technology and Jiangsu Alphamab Oncology for the first-line treatment of advanced breast cancer, was also included in the priority review procedure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.